{"id":"W2765923679","doi":"10.1016/j.clinthera.2017.10.002","title":"Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)","year":2017,"lang":"en","type":"article","venue":"Clinical Therapeutics","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Medicine; Dulaglutide; Insulin glargine; Placebo; Diabetes mellitus; Type 2 diabetes; Internal medicine; Repeated measures design; Urology; Exenatide; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008982534,0.0002669796,0.0006236911,0.0004174335,0.0002639815,0.000821373,0.000292516,0.0005600196,0.001467963],"category_scores_gemma":[0.00322108,0.0001251061,0.001359778,0.0006429373,0.0001882479,0.0005709376,0.000452627,0.0009651838,0.0001320207],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004276577,"about_ca_system_score_gemma":0.0003057602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00203957,"about_ca_topic_score_gemma":0.003120277,"domain_scores_codex":[0.9994524,0.0001953577,0.0000887178,0.0000734567,0.000100461,0.00008956093],"domain_scores_gemma":[0.9978514,0.0005060342,0.001060525,0.0000466851,0.0001355979,0.0003998148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.004651569,0.0005011667,0.9862702,0.0001049358,0.001033206,0.0001205524,0.00008980776,0.0002429244,0.0001508197,0.00003444731,0.0003632781,0.006436998],"study_design_scores_gemma":[0.0003082937,0.001951458,0.9958069,0.00004098937,0.0005625697,0.0002066469,0.0002400706,0.0004711787,0.00007773603,0.0000475427,0.0002670198,0.00001956698],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974869,0.0008602728,0.00004004709,0.0001249757,0.00003112254,0.00001181542,0.0005791011,0.000003274631,0.0008623822],"genre_scores_gemma":[0.9986688,0.0002804757,0.00005741449,0.00007821599,0.0000283608,0.0000123579,0.0007030878,0.000001065672,0.0001702187],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00203957,"threshold_uncertainty_score":0.004910886,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04830368495985739,"score_gpt":0.3371819936526016,"score_spread":0.2888783086927442,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}